BUSINESS WIRE: AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010


LYON, France --(BUSINESS WIRE)-- 09.04.2024 --

Brenus Pharma unveils groundbreaking results during the American Association Cancer Research (AACR) Annual meeting 2024 – San Diego (April 5-10).

“Efficacy of the STC-10101 a new allogeneic cancer vaccine in different colorectal cancer models” | Abstract 5003

This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.

Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.

STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors. Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured. Metastasis reduction has also been shown with in-ovo model.

Results show the potential of STC-1010 in clinical settings to treat patients with colorectal cancer causing 9.7 million death per year.

  • George ALZEEB2,, Innovation Manager Manager (Ph.D)
  • Céline GONGORA3,, Research Director, Head of Team Inserm U1194 “Drug resistances and new cancer treatment” (Ph.D)
  • Corentin RICHARD4,, Postdoctoral Bioiformatician (Ph.D)
  • Romain BOIDOT3,, Molecular Biologist (Ph.D)
  • Tanguy FORTIN5,, Chief Executive Officer (Ph.D)
  • Yan WANG6,, Scientist/R&D Project Manager (Ph.D)
  • Alban BESSEDE7,, Chief Executive Officer (Ph.D)
  • Benoit PINTEUR1,, Chief Scientific Officer (Pharm D)
  • Lionel CHALUS1,, Head of Technical Operation
  • Corinne TORTORELLI1,, Senior Medical Lead (Pharm.D., Ph.D)
  • Paul BRAVETTI1,, Chief Executive Officer (Pharm D, MSc)
  • François GHIRINGHELLI8,, Head of Team Inserm 1231 TIRECs «Therapies and Immune REsponse in CancerS », Director of early clinical unit CLIPP2, Professor of Oncology (M.D, PhD) | Follow us on LinkedIn

1 STC-1010 is a next-generation cancer immunotherapy produced by Allogeneic STC's proprietary Brenus platform. It’s specifically designed to combat colorectal cancer including MSS and MSI-H populations in its first line of treatment for the first indication. STC Platform mimics relapse conditions and allows eduction of patient’s immune system against resistant tumor.
2 Brenus Pharma, Lyon, France,
3 INSERM U1194 IRCM, Montpellier, France,
4 CNRS 6302, Dijon, France,
5 Anaquant, Lyon, France
6 Inovotion, La Tronche, France,
7 Explicyte, Bordeaux, France
8 Inserm 1231 CGFL, Dijon, France | (+33) 787768772